586373-76-4 Usage
Uses
Used in Pharmaceutical Industry:
ISOQUINOLINE, 5-(BROMOMETHYL)-, HYDROBROMIDE (1:1) is used as an intermediate compound for the synthesis of various pharmaceutical drugs. Its unique structure allows it to be a key component in the development of new medications, particularly those targeting neurological disorders and pain management.
Used in Chemical Research:
In the field of chemical research, ISOQUINOLINE, 5-(BROMOMETHYL)-, HYDROBROMIDE (1:1) serves as a valuable research tool for studying the properties and reactions of isoquinoline derivatives. Its reactivity and structural characteristics make it an important subject for understanding the behavior of related compounds and their potential applications in various chemical processes.
Used in Material Science:
ISOQUINOLINE, 5-(BROMOMETHYL)-, HYDROBROMIDE (1:1) is used as a building block in the development of new materials with unique properties. Its incorporation into polymers and other materials can lead to the creation of novel substances with enhanced characteristics, such as improved thermal stability, electrical conductivity, or mechanical strength.
Used in Environmental Remediation:
Although ISOQUINOLINE, 5-(BROMOMETHYL)-, HYDROBROMIDE (1:1) is regulated due to its potential adverse effects, it can be used in environmental remediation processes. Its ability to form complexes with certain metal ions makes it a potential candidate for the removal of toxic metals from contaminated water or soil, contributing to the development of more sustainable and eco-friendly solutions for environmental protection.
Check Digit Verification of cas no
The CAS Registry Mumber 586373-76-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 5,8,6,3,7 and 3 respectively; the second part has 2 digits, 7 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 586373-76:
(8*5)+(7*8)+(6*6)+(5*3)+(4*7)+(3*3)+(2*7)+(1*6)=204
204 % 10 = 4
So 586373-76-4 is a valid CAS Registry Number.
586373-76-4Relevant academic research and scientific papers
Discovery of novel 2,5-dioxoimidazolidine-based P2X7 receptor antagonists as constrained analogues of KN62
Park, Jin-Hee,Lee, Ga-Eun,Lee, So-Deok,Hien, Tran Thi,Kim, Sujin,Yang, Jin Won,Cho, Joong-Heui,Ko, Hyojin,Lim, Sung-Chul,Kim, Yoon-Gyoon,Kang, Keon-Wook,Kim, Yong-Chul
, p. 2114 - 2134 (2015/03/30)
Novel 2,5-dioxoimidazolidine-based conformationally constrained analogues of KN62 (1) were developed as P2X7 receptor (P2X7R) antagonists using a rigidification strategy of the tyrosine backbone of 1. SAR analysis of the 2,5-dioxoimidazolidine scaffold indicated that piperidine substitution at the N3 position and no substitution at N1 position were preferable. Further optimization of the substituents at the piperidine nitrogen and the spacer around the skeleton resulted in several superior antagonists to 1, including 1-adamantanecarbonyl analogue 21i (IC50 = 23 nM in ethidium uptake assay; IC50 = 14 nM in IL-1β ELISA assay) and (3-CF3-4-Cl)benzoyl analogue (-)-21w (54 nM in ethidium uptake assay; 9 nM in IL-1β ELISA assay), which was more potent than the corresponding (+) isomer. Compound 21w displayed potent inhibitory activity in an ex vivo model of LTP-induced pain signaling in the spinal cord and significant anti-inflammatory activity in in vivo models of carrageenan-induced paw edema and type II collagen-induced joint arthritis.
